Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast for Oral Lichen Planus
NCT03836885Phase 2Withdrawn
- Sponsor
- Sunnybrook Health Sciences Centre
- Start
- Nov 2019
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in oral lichen planus (OLP) comparing Apremilast with Placebo (2 arms). Primary endpoint: Treatment success defined as Physician Global Assessment (PhGA) of 0 or 1 at 16 weeks. Planned start Nov 2019; status: withdrawn.
02
Drugs
apremilast
03
Conditions
oral lichen planus (OLP)
Beyond the preview
Go deeper on NCT03836885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03836885.